At INTERPHEX 2024, Wenyu Zhang, PhD, covered new trends in the aseptic industry and the key factors companies should consider while weighing their options.
This investment will bolster the company’s large-scale cell culture CDMO business at its planned Fujifilm Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina.
The collaboration aims to reduce manufacturing time and costs, allowing more access to specialized cancer treatments.
Univercells and Altamira Therapeutics are collaborating on nanoparticle-delivered mRNA vaccines, while Andelyn Biosciences and Grace Science are partnering on novel therapies for NGLY1 deficiency.
A look at the newest innovations offers a deeper understanding of affinity ligands and their role in the future of downstream processing.
There are considerations companies may want to consider before seeking out a service provider.
AstraZeneca’s acquisition of Amolyt Pharma includes eneboparatide, a Phase III therapeutic peptide for the treatment of hypoparathyroidism.
The partnership will allow for both companies to provide end-to-end biopharmaceutical manufacturing solutions.
The immune-resetting peptide, developed by Revolo Biotherapeutics, received positive results from its Phase IIb study.
The acquisition adds a potential rare disease asset to Sanofi’s alpha-1 antitrypsin deficiency pipeline.